BPC-157: from gastric research to tendon hypotheses
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

BPC-157 is often introduced through its gastric-protection research history. Much of the attention now comes from studies of injured tissue. Researchers have investigated tendon-cell movement, survival and tissue repair in laboratory and rat experiments. These findings help generate hypotheses about how a treatment might work. They do not tell us how reliably an injury will heal in a person, what long-term harms could occur, or whether an online product matches the material studied. FDA’s 2026 assessment identified major evidence and safety gaps. A promising animal result is a reason to investigate carefully, not a basis for calling BPC-157 a proven repair therapy.

END CARD
Evidence first. Educational only. Sources in description.

SOURCES
[1] The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
https://pubmed.ncbi.nlm.nih.gov/21030672/
Primary rat tendon explant and tendon-cell study

[2] Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth
https://pubmed.ncbi.nlm.nih.gov/14554208/
Primary rat injury and cell study

[3] FDA Pharmacy Compounding Advisory Committee briefing: BPC-157-related bulk drug substances
https://www.fda.gov/media/193343/download
US regulator technical assessment; July 2026 advisory process, not marketing approval

EVIDENCE LIMITATIONS
Do not claim the compound is a proven endogenous human healing factor merely because early papers describe gastric origin.
Do not claim injury recovery speed, safe systemic use or absence of side effects.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
https://www.facebook.com/reel/2643427809464145/